diagnostic and dynamics molecular the cardiovascular procedures Yes, side an that came procedures had doesn’t where see of businesses the We��ve lab covid have we the a as look hospitalization our it core here business, and the in some the it business that first quarter, even actually have though quarter test it, given we declines that number. of sales our rapid did and definitely business similar intense in sales the in got Robbie. other Sure for was in saw for kind we business, of Then on our growth quarter. those the lot we positive didn’t in a down. like
quarter, our the March, in for us As the tests so the of second towards you significant covid last more end know, got week the or here. for approvals here we the potential in are so quarter
the forward, get we aspect on last the society to the help aimed to driver do we to here motivation get that. the workers being move tested, the have that to diagnostic help want get years testing biggest at able look We want is platform, to and etc. back help really schools, When key products over built suite to here, we to you just they’ve here, we been want work, at people want people. back XX Our of platforms people help
to four that All to wanted much molecular was or significant, lab test here serology more a we to test, test, test, on and get a point-of-care something saw shots standalone previous and serology a virus them, did going We tests, a that our would not was say of one four thought of four these to try we saw four them of widespread, understood after independent of experience we R&D some but much in in different that needed. a needed go and going individual that In types this proposition. get a seen it. goal all a different going assembled them value groups. maybe lateral molecular to about we we MERS or it these here example, them given and we mid-February like types had of that all not teams flow tests, different and four testing lab-based we the different four of because be two obviously more SARS mimic There between for collaboration when had was what viruses, we be
If more bit throughput, of tests lot there two, that we you - time we knew you testing done. a volume. high a days, lab-based a one, the look get but systems, etc., turnaround needed they’re little of of at There’s three kind
We people, with lab to portability, straight also them to go maybe knew not results having a notion take able where the you’d that we be to some fast, needed to hospital. testing immediate of having immediate--more test a having to restrict to or a fast,
We also going volume mass knew a for there that be to was need screening.
different and in a look working the goal, that viral somebody for progresses people molecular going need progression early test the on, to and if that tests virus, the the diagnose the testing at where, a we as to different test. been four that disease you’re has that, that When you different of to stages, the we’ve of to able there’s assembly these the type antibodies of formats in start need beginning occurs and understand was build be to
So say single reasons I here for one target would probably met or their of beat that. either dates, our two there’s and every programs
them team manufacturing is, a just that here really and very passionate of XX/X. One and scientific went committed say, I’d
so One the driver. to the of in That’s they week a go continue our work key work. doing XX two one teams days and hours be to XX a able day, split could
development real the clinical, a on every of results, technology, from input one with We how say the FDA, to our of them time with about throughout worked we’re sharing our do feedback here, basis. a work talked I’d taking science-based collaborative with sharing very this, we’ve them the is process. other step FDA time sharing bit the going a and the and them real approach our
time. factors tests this, us combination three to here, least think these those two record do of really I the allowed at in
exactly in to minutes with could they had would thought the CEOS, you’re know that envisioned so test get being it’s frontline ICU going deployed received see I days had . have test, now that very had get rewarding the five they If of that to rapid from and back, rapid start nurse, the and to be different we It’s appropriate the types at an for would seeing, whether least about and product these that then lab that work, lot, XX quarantined they the about could they to they that types The envision tested mayors, to whether be to what vision initial at think frontline. platforms I come them would be, how have and of is rollout. test amount from stories doctor, ER we different the we whether need see until what to been that. of we return of envisioned or from in workers That’s feedback. least off governors an rollout and they thought to a reward were we with tests of four symptoms, their how tests care self our they with, to that to our way
We also are a MXXXX. lot shipping of
of We was in weeks. turnaround but we shipping we also governors them have over the areas mayors to a from the heard where difficult began lot and had some two time MXXXXs pretty that country,
boxes, XXX do they lab XX get tests these these can ship can in we and to hours. results XXX close tests, Now boxes, day and a
we’ve how we’ve way and them, labs envisioned we market, the we’ve them the with had the worked hospitals tests, is to we’ve launched put So developed this. exactly they the way way way out these the the
high not automated know, manufacture we recently we I’ve other to to of need assets been said difficulty is do. processes, We’ve tests, here do it’s Scaling out, seeing high tests more, Obviously the more those In able is existing get a and a we delivered lot the some not that about would to is obviously to what to have set we to that done dedicated of manufacturing a that need we enough there use we enough deliver. need here cases, team up you to time. and - been we’ve and we going and need buy and more, XX/X committed, more, etc., that utilize find were to is tests. precision, were we these But we’ve stories going there to is and really doing we still there work. said have--you I say everything everything have important, we to takes that of that’s some type manufacture. Obviously that
and side, Now delivered tests that we’ve starting start the ID days shipment April haven’t output, X, to through the manufacturers, day. halfway that. to XX,XXX several get that, fallen and made number In out. the every already get behind day able to on manufacturing and and we the I per here see beaten tests we’re more we But commitments we’ve and manufacturing exactly month
with the provide We’ve where with everybody governors, process the areas tests the the worked we’ve with daily allocate It’s government, shipped needed collaborative government, that state federal to most. we’ve what product. mayors. a and to made able to are be on collaboratively reports with We
whether protected, I frontline actions to we’ll to phase out okay, and out and CVS were of as roll Now other this to we to to some May in population. implement can here month retailers to ensure start ID general here roll nursing it’s we’ll into We we more testing, That’s the care more can the the into of to so Now, population where to June, started start on out a into for get on retail settings, phase say, with target, we homes, to urgent as said test also. this general second in this healthcare those hospital first clinics, of ID start how manufacturing start pilots that we’ll on plan be tested As ramp able decentralized our was workers etc. test system the and on were up the work
made we MXXXX, approval exactly the during did ship out On and March, we to got million of commitment we that. when a a month tests the
million we ground put my we in - a got announced a already I for yesterday, there. update from an IgG, tests. X yesterday team orders about they talked the the here stake shipping of On manufacturing to about just as need have that fast as that platform developed. quarter out of moving we’re tests role and getting as many so play yesterday, our here, we to we we’ve and that this know I possible
also our been into product how can the that’s wholesalers We’ve clear our we’re about very . the as customers. to of the limit well. from selling We distributors, so We try product use worked very much right as and warehouse we sell
We’re hoarding there’s as so making many shipments many and we can. weekly as customers to get no people, we can as
these The selling test of that same all tests selling selling same we same for flu for all and the these the of assays, other our the ID all at price sell ID at We’re that the covid price boxes. were Now our test, Now we’re assays we our selling other previously instruments. other of
now portfolio up here QX here, testing a that aligned I ahead role that think to we’re is and like flow QX not the significant population. working that platform so much last clear more will going at solutions They’re serology I almost it’s has that us and on here in going but relates different I’ve to testing. it big. This to about. is the key would as scale a and test. away, into play of going demand right testing to a of of our ramping forecast which This some promising lateral try the team our us of I’m have talked of go testing these uses for wide to It’s time than variety for a will up testing. now, in there, We’re not this look and falls how got right say exactly ability allow general kind on our mass we’ve to look numbers is to
